| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f3a218a73266e3df2aacace1fefbbda |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1787
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8645 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f6f8e50d21fe738696c09e37cd2e0cd |
| publicationDate |
2020-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200100735-A |
| titleOfInvention |
Use of hM4Di in the treatment of seizure disorders |
| abstract |
Methods and compositions for treating seizure disorders are provided, the method comprising administering to a patient an adeno-associated viral vector encoding hM4Di to deliver hM4Di to a target location; And administering to the patient a synthetic ligand that activates hM4Di, wherein the vector comprises a human or murine CaMKII promoter, a regulatory element after marmoset hepatitis virus transcription, and a bovine growth hormone polyadenylation sequence. Administration of vectors and synthetic ligands to patients with seizure disorders is associated with reduced symptoms of seizure disorders. In an embodiment, ultrasound is applied to a target location in the patient's brain to improve the permeability of the patient's blood brain barrier to vectors and/or synthetic ligands. |
| priorityDate |
2017-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |